Mirati Therapeutics, Inc. (MRTX) Shares Bought by Royce & Associates LP
Royce & Associates LP boosted its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by 88.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 251,100 shares of the biotechnology company’s stock after acquiring an additional 118,063 shares during the quarter. Royce & Associates LP owned 1.01% of Mirati Therapeutics worth $917,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. LMR Partners LLP purchased a new position in Mirati Therapeutics during the 2nd quarter valued at about $236,000. Boxer Capital LLC boosted its holdings in Mirati Therapeutics by 37.0% during the 1st quarter. Boxer Capital LLC now owns 1,037,994 shares of the biotechnology company’s stock valued at $5,398,000 after acquiring an additional 280,059 shares during the period. Aviva Holdings Ltd. boosted its holdings in Mirati Therapeutics by 44.6% during the 1st quarter. Aviva Holdings Ltd. now owns 2,880,702 shares of the biotechnology company’s stock valued at $14,980,000 after acquiring an additional 888,617 shares during the period. Sabby Management LLC boosted its holdings in Mirati Therapeutics by 150.4% during the 1st quarter. Sabby Management LLC now owns 249,735 shares of the biotechnology company’s stock valued at $1,299,000 after acquiring an additional 150,000 shares during the period. Finally, Omega Advisors Inc. purchased a new position in Mirati Therapeutics during the 1st quarter valued at about $520,000. Institutional investors own 60.17% of the company’s stock.
A number of equities analysts recently commented on MRTX shares. ValuEngine cut Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Jefferies Group LLC restated a “hold” rating and set a $4.50 target price on shares of Mirati Therapeutics in a report on Monday, June 12th. Finally, Leerink Swann raised their target price on Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $8.15.
Shares of Mirati Therapeutics, Inc. (NASDAQ MRTX) opened at 11.20 on Friday. Mirati Therapeutics, Inc. has a 52-week low of $2.70 and a 52-week high of $12.40. The firm’s market cap is $279.65 million. The firm has a 50-day moving average price of $5.21 and a 200-day moving average price of $4.48.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.